7th Nov 2014 08:49
LONDON (Alliance News) - Biofrontera AG on Friday said it has signed a deal with Allergan SA under which it will take over distribution, sales and marketing for the Ameluz and BF-RhodoLED products in Spain.
Biofrontera said the key account manager for dermatology at Allergan will transfer to Biofrontera in order to continue working on the Ameluz account. It did not name the manager.
The new distribution deal will start in March 2015.
Ameluz and BF-RhodoLED are the company's skin cancer treatments.
Shares in Biofrontera were untraded on Friday, having last traded at 235.00 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
B8F.L